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Introduction
Musculoskeletal research is mostly clinical and participa-
tion of human subjects is extremely common. It shares
most features with all the surgical research fields, with
studies on operative procedures largely prevailing over
those on pharmacological interventions. In the orthopedic
research scenario, prostheses and other implantable hard-
ware often correspond to the role that drugs play in medical
research, with no less potential harm for the populations
studied. Not rarely, vulnerable categories are involved, for
instance children in pediatric orthopedics. In the emerging
branch of musculoskeletal regenerative medicine, embry-
onic stem cells are not used, but only adult somatic stem
cells, which considerably reduces but does not remove the
ethical issues connected with these new applications.
Given these premises, guaranteeing human subjects
protection is mandatory for authors, editors and publishers,
firstly because ‘‘the health of my patient will be my first
consideration’’ (from the World Medical Association
Declaration of Geneva [1]), but also because biomedical
publishing is not exempt from possible litigation. Since
editors are ultimately responsible for what is published,
they have to enforce strict requirements to ensure that
proper ethical standards are fulfilled. Sometimes such
requirements seem to subject authors to a burden of
paperwork that equals the scientific effort, but intolerance
of this is generated by a misinterpretation: science and
ethics cannot stand alone, nor can they be neatly separated
in any research project.
There are three milestones of ethical human research:
the Declaration of Helsinki, informed consent and ethics
committee approval. Most journals, as we do at Journal of
Orthopaedic Traumatology, ask authors to make a precise
statement under their own responsibility to guarantee that
these requirements are met. But formally reporting ade-
quate ethical standards cannot be considered sufficient for
publication, if anywhere along the process of manuscript
review relevant concerns are raised about the substantive
ethical conduct of the investigators.
Defining the boundaries of ‘‘research involving
human subjects’’
In most cases connected with musculoskeletal research and
publishing, the definition of study involving human par-
ticipants is obvious and unquestionable. However, we
ought to consider some special cases in which this
assignment might be debatable.
In certain legislative scenarios, the first part of the def-
inition, ‘‘research’’, might be questioned. As we will dis-
cuss later, in UK service evaluation, audit and public health
surveillance are not considered research as they are not
meant to produce new generalizable knowledge [2]. These
studies may then be conducted with less formal require-
ments than properly defined research studies.
However, the most interesting grey area is represented
by the second part of the definition, ‘‘involving human
subjects’’. Does research based on human specimens, cells,
cell lines or simple data involve human subjects? The
regulation differs between countries. In the USA we find
the clearest answer: human subjects are involved if
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specimens, cells or data are obtained from living individ-
uals by the investigators through direct intervention/inter-
action or, alternatively, if investigators obtain identifiable
private information linked to the items. This means that
cadaver studies and all studies in which repositories like
biobanks and databases provide the investigators with
coded items without releasing the key that permits them to
ascertain the identity of the living subjects to whom
data/cells/specimens pertain, do not involve human sub-
jects [3]. The EU regulation does not address the issue with
equal clarity. The Recommendation Rec(2006)4 of the
Committee of Ministers to member states on research on
biological materials of human origin [4] states that research
on identifiable biological materials should be performed
only with the specific consent of the person concerned,
while research on unlinked anonymized biological mate-
rials is permitted if no donor’s restriction is violated. But
the same recommendation requires that anonymization be
assessed by an appropriate review procedure, which means,
in other words, that to be prudent all studies on biological
materials are equated to human research. However, since
the recommendation is not legally binding, researchers
should refer to their own national legislation for specific
requirements.
The Declaration of Helsinki
The Declaration of Helsinki was adopted by the 18th
World Medical Association General Assembly in 1964 and
recently amended in 2013 [5]. It states the ‘‘Ethical Prin-
ciples for Medical Research Involving Human Subjects’’,
including protecting the life, health and privacy of all
patients or healthy subjects, guaranteeing voluntary and
informed participation, and requesting an external ethical
review of the research projects and the appropriate regis-
tration of clinical trials in a public database in order to
minimize the risk of selective reporting of results and to
avoid unnecessary duplication of research projects.
According to the International Committee of Medical
Journal Editors (ICMJE), registration is mandatory for all
prospective studies, comparative or not, that expose the
subjects to a health-related intervention (i.e. surgical pro-
cedure or drug administration) and evaluate its outcome.
The International Clinical Trials Registry Platform
(ICTRP) [6] lists the registries that have been tested and
approved by the World Health Organization and accepted
by the ICMJE. ClinicalTrials.gov is equally accepted as a
data provider to ICTRP.
When authors state, under their own responsibility, that
‘‘the study conforms to the Declaration of Helsinki’’, they
actually guarantee that all the above principles were
observed. The following two statements about informed
consent and ethics committee approval might be consid-
ered pleonastic, as they are already entailed by adherence
to the Declaration. However, these additional claims mean
to substantiate the ethical conduct of the study through
objective documentation, available upon request by the
journal, while the assertion to have followed the Helsinki
principles might rely subjectively on the authors’
judgement.
Informed consent
The Council for International Organizations of Medical
Sciences (CIOMS) International Ethical Guidelines for
Biomedical Research Involving Human Subjects [7]
clearly state that all the human subjects enrolled in a study
must provide a voluntary informed consent (Guideline 4);
it should be obtained after a thorough explanation of the
objects and methods, as well as of the possible risks and
benefits, giving the subject the chance to revoke their
adherence at any time throughout the study. In pediatric
orthopedics, the consent must be expressed by the parents
(or by any other legally authorized representatives), but if
the child’s age allows adequate comprehension, their
opinion should be sought and not swayed by the parents’
judgement, namely in the case of refusal (CIOMS Guide-
line 14). The informed consent should be expressed in
writing, and the signed consent form should be stored by
the investigators. Exceptionally, other types of documen-
tation can be accepted (i.e. recording or witnessing). The
documents should be made available to the editors upon
request.
Waiver of the informed consent is a rare occurrence,
which must always be provided by the competent ethics
committee (EC). When a study involves no more than
extracting data from medical records and no potential harm
to the studied population is determined, and anonymity and
confidentiality are properly safeguarded, such as in retro-
spective chart reviews, the ethics committee may decide to
waive the informed consent, if the study might not be
feasible otherwise. Any waiver of or alteration to the for-
mal consent requirements provided by the responsible EC
must be reported in the Ethical Standards statement.
A different consent form should be obtained from
patients when identifying information is published (i.e.
clinical pictures in which anonymization cannot be reliably
performed without distorting the scientific meaning of the
figure); this is a consent to publish identifiable information
about the subject, who should be made aware of what kind
of material will be displayed and should accept the corre-
sponding privacy violation.
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Ethics committee (EC) or Institutional Review
Board (IRB)
CIOMS ethical guideline 2 requires that ‘‘all proposals to
conduct research involving human subjects must be sub-
mitted for review of their scientific merit and ethical
acceptability to one or more scientific review and ethical
review committees’’ [7]. This statement implies that
investigators have to obtain clearance from an external and
independent body of reviewers before any kind of research
project is started. Ethics committees are designed to
include members with different fields of expertise, in order
to carry out both the scientific and the ethical review; a
research protocol with poor scientific basis is a waste of
resources and might involve unjustified harm to the studied
population, and thus is as ethically unacceptable as a study
whose protocol shows an unbalanced risk–benefit ratio.
The organization of ECs varies across countries: in
Europe there are national, regional, local and institutional
Research Ethics Committees, whose responsibility is
determined by local laws. The new Clinical Trials Regu-
lation EU No 536/2014 [8], expected to apply no earlier
than May 2016, should favor the harmonization of clinical
trials authorization in the European Union, but is not
supposed to interfere with the national organization of ECs.
Researchers should then continue to refer to their national
legislation. In Italy, for instance, ECs were recently reor-
ganized by Regions to comply with the standard of one
Committee per million inhabitants, and are made up of
about 20 members in position for 3 years. Additional
Ethics Committees were also identified in scientific hos-
pitalization and care institutions (IRCCS) [9]. In the USA
the corresponding entity is named an Institutional Review
Board (IRB), is represented by at least five members with
different backgrounds to cover the area of research, is set
up at the level of medical and academic institutions, and is
regulated by the Office for Human Research Protections
(OHRP) within the Department of Health and Human
Services (HHS). Commercial or independent IRBs from
for-profit organizations are also in existence and equally
acceptable, as they are subjected to the same US Federal
Rules [3].
Obtaining clearance from the responsible EC/IRB
implies that an external body of reviewers, independent
from the investigators, has verified that the research is
scientifically sound, that the potential risks to the subjects
involved are minimized and reasonable in relation to the
anticipated benefits, that the participants are equitably
selected and thoroughly informed, that consent is properly
obtained, and that privacy and confidentiality are protected
as well as the welfare and rights of special vulnerable
categories.
Exemption from EC/IRB approval is considered in
certain cases under special legislation. In the UK, for
example, the Health Research Authority waives the ethical
review for projects on service evaluation (designed to
measure the standards of care provided by a health ser-
vice), clinical audit (designed to test a service against a
predetermined standard) and public health surveillance
(designed to manage outbreaks). All these projects are
considered outside the scope of research, as they do not
create new generalizable knowledge [2]. Since the intent of
such projects is rarely the publication of scientific papers, it
seldom occurs but, in that event, especially if the paper is
submitted to international or non-UK journals, the editors
might question the missing EC/IRB clearance. We at
Journal of Orthopaedic Traumatology adopt the recom-
mendation of the Committee on Publication Ethics (COPE)
[10] and consider the paper acceptable if no ethical con-
cerns can be raised. Similarly US Federal Rule 45 CFR 46
states that ‘‘Research involving the collection or study of
existing data, documents, records, pathological specimens,
or diagnostic specimens, if these sources are publicly
available or if the information is recorded by the investi-
gator in such a manner that subjects cannot be identified,
directly or through identifiers linked to the subjects’’ is
exempt from the Basic HHS Policy for Protection of
Human Research Subjects, and may then avoid IRB
approval [3]. To avoid misunderstandings that might
compromise the acceptance of the manuscript, in such
cases authors are advised to: (1) seek the judgement of an
IRB/EC representative about exemption instead of making
the decision by themselves; (2) cite the national legislation
permitting the exemption in the Ethical Standards state-
ment; (3) provide a careful description in Materials and
Methods of the procedures meant to minimize the risks to
health, privacy and confidentiality of the subjects involved.
Ethical review and Editors’ responsibility
As the protocol evaluation by the EC/IRB cannot neatly
separate scientific and ethical assessment, similarly the
manuscript evaluation occurring in any peer-reviewed
journal ought to consider both these aspects before
expressing a final decision on acceptance or rejection. In
most journals, such as in Journal of Orthopaedic Trau-
matology, the first manuscript screening by the Editorial
Office already checks the conformity to the ethical
requirements reported in the Instructions for Authors. This
is merely a formal evaluation, aimed at avoiding misun-
derstandings and oversights in the preparation of the Eth-
ical Standards statement. The second line of ethical review
is represented by peer review itself. Not rarely the referees
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raise concerns or ask for clarification about ethical issues
connected with the study protocol. Such an attitude should
be encouraged and promoted. The third line of ethical
review is commonly performed by editors, who are ulti-
mately responsible for whatever is published in their
journals. Formal conformity to the main ethical require-
ments (adherence to the Declaration of Helsinki, informed
consent, EC/IRB approval) does not guarantee a positive
assessment. In doubtful cases the editor may ask the
authors to provide protocol documentation, informed con-
sents, EC/IRB reports, or simply more methodological
details to form their own judgement about the conduct of
the research. In exceptionally critical cases they are entitled
to contact the EC/IRB, or even to ask the authors to obtain
an additional external review.
Safeguarding the health, welfare, privacy and confi-
dentiality of research participants is a heavy responsibility
for editors, and rejection on ethical grounds is a rare but
sometimes necessary occurrence, as unpopular among
authors who receive it as it is among editors who have to
determine it. In some cases the reasons for this extreme
decision lie in poor protocol planning, in a limited
knowledge of rules and legislation, or simply in underes-
timating the ethical issues against the scientific ones.
However, most ethical concerns arising throughout the
review process are merely formal and could be reasonably
solved in advance with a careful preparation of the Ethical
Standard statement and a detailed description of the risk
minimization procedures within the Materials and Methods
section. Should further questions be raised, authors are
encouraged to provide the journal with all the available
information and documentation for an appropriate ethical
assessment. To every wise editor, the value of a substan-
tively ethical study will always prevail over a minor non-
compliance with formal requirements, as long as the
authors cooperate with the journal to elaborate and clarify.
Final recommendations for authors
The ‘‘golden triad’’ of ethical human research—conformity
to the Declaration of Helsinki, informed consent, EC/IRB
clearance—is the fundamental Ethical Standards statement
that authors should be ready to make for most muscu-
loskeletal research manuscripts. Whenever an exemption
from the second or the third requirement is obtained, the
local rules or laws allowing the exemption or the EC
decision about consent waiver should be reported. Lastly,
all the critical issues regarding the protection of the human
participants should be clearly addressed in Materials and
Methods, as they are at least as relevant as the scientific
issues in evaluating the global quality of the research and
its eventual publishability.
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